Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated patients with recurrent glioblastoma: A single-institution analysis

Journal of Neuro-Oncology

Volumn 109, Issue 2, 2012, Pages 433-438

  Kuhnhenn, Jan ^a   Kowalski, Thomas ^a   Steenken, Sabine ^a   Ostermann, Kathrin ^a   Schlegel, Uwe ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Recurrent glioblastoma; Salvage chemotherapy

Indexed keywords

CARMUSTINE; DEXAMETHASONE; DOXORUBICIN; IMATINIB; LIVER ENZYME; NIMOTUZUMAB; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANEMIA; ARTICLE; ASTROCYTOMA; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER SURVIVOR; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RECURRENT CANCER; REOPERATION; RETROSPECTIVE STUDY; SALVAGE THERAPY; SIDE EFFECT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARMUSTINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROCARBAZINE; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVORS; VINCRISTINE;

EID: 84866024528     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0913-5     Document Type: Article

References (43)

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study:5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459-466
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996 (Pubitemid 40349501)
3. Mandl ES, Dirven CM, Buis DR, Postma TJ, Vandertop WP (2008) Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy. Surg Neurol 69(5):506-509
4. Nieder C, Astner ST, Mehta MP, Grosu AL, Molls M (2008) Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma. Am J Clin Oncol 31(3):300-305
5. Combs SE, Gutwein S, Thilmann Ch, Huber P, Debus J, Schulz-Ertner D (2005) Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme. J Neurooncol 74(2):167-171 (Pubitemid 41478913)
6. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, Meyermann R, Reifenberger G, Weller M, Wick W (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25(22):3357-3361 (Pubitemid 47325623)
7. Wick A, Pascher C, Wick W, Jauch T, Weller M, Bogdahn U, Hau P (2009) Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol 256(5):734-741
8. Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, Biscuola M, Blatt V, Crinò L, Ermani M (2006) Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 95(9):1155-1160 (Pubitemid 44658477)
9. Brandes AA, Ermani M, Basso U, Amistà P, Berti F, Scienza R, Rotilio A, Pinna G, Gardiman M, Monfardini S (2001) Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. Ann Oncol 12(2):255-257 (Pubitemid 32223878)
10. van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, Clement PM, Frenay M, Campone M, Baurain JF, Armand JP, Taphoorn MJ, Tosoni A, Kletzl H, Klughammer B, Lacombe D, Gorlia T (2009) Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 27(8):1268-1274
11. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83(5):588-593 (Pubitemid 30636298)
12. Happold C, Roth P, Wick W, Steinbach JP, Linnebank M, Weller M, Eisele G (2009) ACNU-based chemotherapy for recurrent glioma in the temozolomide era. J Neurooncol 92(1):45-48
13. Brandes AA, Tosoni A, Amistà P, Nicolardi L, Grosso D, Berti F, Ermani M (2004) How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology 63(7):1281-1284 (Pubitemid 39350031)
14. Rosenthal MA, Ashley DL, Cher L (2004) BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide. J Clin Neurosci 11(4):374-375 (Pubitemid 38568473)
15. Reithmeier T, Graf E, Piroth T, Trippel M, Pinsker MO, Nikkhah G (2010) BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors. BMC Cancer 2(10):30
16. Wolfgang W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, Liepa AM, Thornton DE, Fine HA (2010) Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28(7):1168-1174
17. Mulholland P, Batchelor TT, Neyns B et al (2010) A phase III randomized study comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, with lomustine alone in recurrent glioblastoma patients. Proc ESMO Ann Oncol 21: LBA7
18. Brandes AA, Tosoni A, Franceschi E, Blatt V, Santoro A, Faedi M, Amistà P, Gardiman M, Labianca R, Bianchini C, Ermani M, Reni M (2009) Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol 64(4):769-775
19. Fabrini MG, Silvano G, Lolli I, Perrone F, Marsella A, Scotti V, Cionini L (2009) A multi-institutional phase II study on secondline Fotemustine chemotherapy in recurrent glioblastoma. J Neurooncol 92(1):79-86
20. Chamberlain MC, Tsao-Wei DD (2004) Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. Cancer 100(6):1213-1220 (Pubitemid 38325950)
21. Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J (2006) A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a orth American brain tumor consortium study. Neuro Oncol 8(2):189-193 (Pubitemid 46542664)
22. Kappelle AC, Postma TJ, Taphoorn MJ, Groeneveld GJ, van den Bent MJ, van Groeningen CJ, Zonnenberg BA, Sneeuw KC, Heimans JJ (2001) PCV chemotherapy for recurrent glioblastoma multiforme. Neurology 56(12):1782 (Pubitemid 32574594)
23. Schmidt F, Fischer J, Herrlinger U, Dietz K, Dichgans J, Weller M (2006) PCV chemotherapy for recurrent glioblastoma. Neurology 66(4):587-589 (Pubitemid 43739895)
24. Silvani A, Lamperti E, Gaviani P, Eoli M, Fiumani A, Salmaggi A, Falcone C, Filippini G, Botturi A, Boiardi A (2008) Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. J Neurooncol 87(2):143-151
25. Brandes AA, Turazzi S, Basso U, Pasetto LM, Guglielmi B, Volpin L, Iuzzolino P, Amistà P, Pinna G, Scienza R, Ermani M (2002) A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme. Neurology 58(12):1759-1764 (Pubitemid 34663574)
26. Gwak HS, Youn SM, Kwon AH, Lee SH, Kim JH, Rhee CH (2005) ACNU-cisplatin continuous infusion chemotherapy as salvage therapy for recurrent glioblastomas: phase II study. J Neurooncol 75(2):173-180 (Pubitemid 41819721)
27. Brandes AA, Tosoni A, Basso U, Reni M, Valduga F, Monfardini S, Amistà P, Nicolardi L, Sotti G, Ermani M (2004) Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 22(23):4779-4786
28. Aoki T, Mizutani T, Nojima K, Takagi T, Okumura R, Yuba Y, Ueba T, Takahashi JA, Miyatake S, Nozaki K, Taki W, Matsutani M (2010) Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme. J Neurosurg 112(1):50-56
29. Glas M, Hundsberger T, Stuplich M, Wiewrodt D, Kurzwelly D, Nguyen-Huu B, Rasch K, Herrlinger U (2009) Nimustine (ACNU) plus teniposide (VM26) in recurrent glioblastoma. Oncology 76(3):184-189
30. Reardon DA, Quinn JA, Rich JN, Gururangan S, Vredenburgh J, Sampson JH, Provenzale JM, Walker A, Badruddoja M, Tourt-Uhlig S, Herndon JE II, Dowell JM, Affronti ML, Jackson S, Allen D, Ziegler K, Silverman S, Bohlin C, Friedman AH, Bigner DD, Friedman HS (2004) Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro Oncol 6(2):134-144 (Pubitemid 38455760)
31. Chua SL, Rosenthal MA, Wong SS, Ashley DM, Woods AM, Dowling A, Cher LM (2004) Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. Neuro Oncol 6(1):38-43 (Pubitemid 38139638)
32. Reardon DA, Quinn JA, Vredenburgh J, Rich JN, Gururangan S, Badruddoja M, Herndon JE 2nd, Dowell JM, Friedman AH, Friedman HS (2005) Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 103(2):329-338 (Pubitemid 40129293)
33. Reardon DA, Dresemann G, Taillibert S, Campone M, van den Bent M, Clement P, Blomquist E, Gordower L, Schultz H, Raizer J, Hau P, Easaw J, Gil M, Tonn J, Gijtenbeek A, Schlegel U, Bergstrom P, Green S, Weir A, Nikolova Z (2009) Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer 101(12):1995-2004
34. Dresemann G, Weller M, Rosenthal MA, Wedding U, Wagner W, Engel E, Heinrich B, Mayer-Steinacker R, Karup-Hansen A, Fluge O, Nowak A, Mehdorn M, Schleyer E, Krex D, Olver IN, Steinbach JP, Hosius C, Sieder C, Sorenson G, Parker R, Nikolova Z (2010) Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neurooncol 96(3):393-402
35. De Witt Hamer PC (2010) Small molecule kinase inhibitors in glioblastoma: a systemic review of clinical studies. Neuro Oncol 12(3):304-316
36. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK (2010) Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28(17):2817-2823
37. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733-4740
38. Chamberlain MC, Johnston SK (2010) Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neurooncol 96(2):259-269
39. Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, Nelson SF, Elashoff R, Cloughesy TF (2009) Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 72(14):1217-1222
40. Vredenburgh JJ, Desjardins A, Herndon JE II, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722-4729 (Pubitemid 350086473)
41. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003. http://www.eortc.be/services/doc/ctc/ctcaev3.pdf
42. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277-1280 (Pubitemid 20195640)
43. Preusser M, de Ribaupierre S, Wöhrer A, Erridge SC, Hegi M, Weller M, Stupp R (2011) Current concepts and management of glioblastoma. Ann Neurol 70(1):9-21